JP2007521015A - 癌の診断及び治療に用いられる示差的に発現する腫瘍特異的ポリペプチド - Google Patents

癌の診断及び治療に用いられる示差的に発現する腫瘍特異的ポリペプチド Download PDF

Info

Publication number
JP2007521015A
JP2007521015A JP2006526617A JP2006526617A JP2007521015A JP 2007521015 A JP2007521015 A JP 2007521015A JP 2006526617 A JP2006526617 A JP 2006526617A JP 2006526617 A JP2006526617 A JP 2006526617A JP 2007521015 A JP2007521015 A JP 2007521015A
Authority
JP
Japan
Prior art keywords
protein
cancer
immunogenic membrane
cell
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006526617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007521015A5 (enExample
Inventor
トーマス ブッシマン，
ニコレッタ−キリヤキ フォーティアディス，
ミリアム フックス，
シテッフェン ハイム，
タティアナ イリニヤ，
シテファニー ラーメア，
ヤーン モイヤー，
キアステン ロートマン−コシック，
フォルカー サイバート，
シルビア， トートラ ペレス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS filed Critical Genmab AS
Publication of JP2007521015A publication Critical patent/JP2007521015A/ja
Publication of JP2007521015A5 publication Critical patent/JP2007521015A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006526617A 2003-09-18 2004-09-20 癌の診断及び治療に用いられる示差的に発現する腫瘍特異的ポリペプチド Pending JP2007521015A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03090307 2003-09-18
US51207803P 2003-10-20 2003-10-20
PCT/EP2004/010780 WO2005026735A2 (en) 2003-09-18 2004-09-20 Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer

Publications (2)

Publication Number Publication Date
JP2007521015A true JP2007521015A (ja) 2007-08-02
JP2007521015A5 JP2007521015A5 (enExample) 2007-11-08

Family

ID=37657558

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006526617A Pending JP2007521015A (ja) 2003-09-18 2004-09-20 癌の診断及び治療に用いられる示差的に発現する腫瘍特異的ポリペプチド

Country Status (10)

Country Link
US (1) US20090252721A1 (enExample)
EP (2) EP2050827A3 (enExample)
JP (1) JP2007521015A (enExample)
CN (1) CN1902326A (enExample)
AU (1) AU2004272747A1 (enExample)
BR (1) BRPI0414446A (enExample)
CA (1) CA2539490A1 (enExample)
IL (1) IL174047A0 (enExample)
SG (1) SG146622A1 (enExample)
WO (1) WO2005026735A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014081365A (ja) * 2012-09-26 2014-05-08 Fujita Gakuen 細胞表面タンパクを抗原とする抗体を測定する方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1854473A1 (en) * 2005-03-03 2007-11-14 Takeda Pharmaceutical Company Limited Preventive/therapeutic agent for cancer
EP1924294A4 (en) 2005-05-24 2010-11-03 Isis Pharmaceuticals Inc COMPOSITIONS AND ITS USES AGAINST PTPRU
PL1951283T3 (pl) * 2005-11-16 2010-12-31 Pantarhei Bioscience Bv Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika
NZ578235A (en) * 2007-02-02 2012-05-25 Novartis Ag Modulators of sclerostin binding partners for treating bone-related disorders
JP2010527633A (ja) * 2007-05-25 2010-08-19 セントコア・オーソ・バイオテツク・インコーポレーテツド Ｔｏｌｌ様受容体３モジュレーター及びその使用
WO2009108215A1 (en) * 2007-09-06 2009-09-03 Aviaradx, Inc. Tumor grading and cancer prognosis
US8158373B2 (en) * 2008-03-25 2012-04-17 Case Western Reserve University Method of detecting cancer and evaluating cancer prognosis
WO2010056993A2 (en) * 2008-11-14 2010-05-20 Emory University Prostate cancer biomarkers to predict recurrence and metastatic potential
US9492472B2 (en) 2008-12-23 2016-11-15 Case Western Reserve University Compositions and methods of treating cancer
WO2011008631A2 (en) 2009-07-16 2011-01-20 Omnova Solutions Inc. Protective coating compositions
JP2013537045A (ja) 2010-09-15 2013-09-30 アルマック ダイアグノスティックス リミテッド 癌のための分子診断試験
US20150301068A1 (en) 2012-01-30 2015-10-22 Vib Vzw Means and method for diagnosis and treatment of alzheimer's disease
IN2014DN06898A (enExample) * 2012-03-14 2015-05-15 Salk Inst For Biological Studi
WO2016080830A2 (en) * 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
CN109646685A (zh) * 2017-10-12 2019-04-19 北京医院 stomatin蛋白及其编码基因在肺癌诊断治疗中的应用
CN111394370B (zh) * 2020-03-03 2022-03-25 华南农业大学 一种猪RagA基因及其应用
CA3172489A1 (en) 2020-03-23 2021-09-30 Amit KHANDHAR Nanoemulsion compositions and methods for delivery of nra
CN114540349B (zh) * 2020-11-27 2024-11-22 中国科学院分子细胞科学卓越创新中心 结合yb-1蛋白的核酸分子
AU2022351009A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Rna vaccines against infectious diseases
EP4404957A4 (en) * 2021-09-22 2025-08-06 Hdt Bio Corp CANCER THERAPY COMPOSITIONS AND THEIR USES
AU2022352486A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Dried nanoparticle compositions
CA3232719A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Sars-cov-2 rna vaccine compositions and methods of use
CN116482367A (zh) * 2023-05-04 2023-07-25 中国中医科学院望京医院(中国中医科学院骨伤科研究所) 一种联合mSEPT9检测和生物标志物的结直肠癌检测方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0003415A3 (en) 1978-01-20 1979-08-22 Glaxo Group Limited Beta-lactam compounds, processes for their preparation,compositions containing them and intermediates of use in their preparation
US4849338A (en) 1982-07-16 1989-07-18 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4843000A (en) 1979-12-26 1989-06-27 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4520110A (en) 1981-10-06 1985-05-28 The Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing a phycobiliprotein labeled ligand or receptor
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4542104A (en) 1983-04-06 1985-09-17 The Board Of Trustees Of The Leland Stanford Jr. Univ. Phycobiliprotein fluorescent conjugates
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB9705949D0 (en) 1997-03-21 1997-05-07 Electrophoretics International Diagnosis of tumours and other abnormalities of body cells
US6197543B1 (en) * 1997-10-28 2001-03-06 Incyte Pharmaceuticals, Inc. Human vesicle membrane protein-like proteins
US6902898B2 (en) * 1998-11-16 2005-06-07 National Institute Of Advanced Industrial Science And Technology Human derived bradeion proteins, DNA coding for the proteins, and uses thereof
EP1033404A1 (en) * 1999-01-29 2000-09-06 F. Hoffmann-La Roche Ag New gene with down-regulated expression in metastatic human melanoma cells
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
WO2001022920A2 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US20030104413A1 (en) * 2000-07-14 2003-06-05 Tang Y. Tom Novel Nucleic acids and polypeptides
US20030108926A1 (en) * 2000-03-15 2003-06-12 Eos Biotechnology, Inc. Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US20020040127A1 (en) * 2000-06-09 2002-04-04 Yuqiu Jiang Compositions and methods for the therapy and diagnosis of colon cancer
AU2001285047A1 (en) * 2000-08-16 2002-02-25 Chiron Corporation Human genes and gene expression products
US20030134283A1 (en) * 2000-10-03 2003-07-17 Peterson David P. Genes regulated in dendritic cell differentiation
US20020160382A1 (en) * 2000-10-11 2002-10-31 Lasek Amy W. Genes expressed in colon cancer
WO2003029273A2 (en) * 2001-09-28 2003-04-10 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
EP1308459A3 (en) * 2001-11-05 2003-07-09 Research Association for Biotechnology Full-length cDNA sequences
JP2006515318A (ja) * 2002-10-29 2006-05-25 ファルマシア・コーポレーション 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010035818, Ｂｉｏｃｈｅｍｉｃａｌ ａｎｄ ｂｉｏｐｈｙｓｉｃａｌ ｒｅｓｅａｒｃｈ ｃｏｍｍｕｎｉｃａｔｉｏｎｓ． ２００１， Ｖｏｌ．２８５， Ｎｏ．５， ｐ．１２４４−１２４９ *
JPN6010035822, Ｂｉｏｃｈｅｍｉｃａｌ ｐｈａｒｍａｃｏｌｏｇｙ． ２００１， Ｖｏｌ．６２， Ｎｏ．１０， ｐ．１３１１−１３３６ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014081365A (ja) * 2012-09-26 2014-05-08 Fujita Gakuen 細胞表面タンパクを抗原とする抗体を測定する方法

Also Published As

Publication number Publication date
IL174047A0 (en) 2006-08-01
US20090252721A1 (en) 2009-10-08
EP2050827A2 (en) 2009-04-22
SG146622A1 (en) 2008-10-30
EP2050827A3 (en) 2009-09-02
WO2005026735A3 (en) 2005-11-03
WO2005026735A2 (en) 2005-03-24
AU2004272747A1 (en) 2005-03-24
BRPI0414446A (pt) 2006-11-14
EP1673470A2 (en) 2006-06-28
CA2539490A1 (en) 2005-03-24
CN1902326A (zh) 2007-01-24

Similar Documents

Publication Publication Date Title
JP2007521015A (ja) 癌の診断及び治療に用いられる示差的に発現する腫瘍特異的ポリペプチド
US11892453B2 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
JP6581247B2 (ja) 前立腺癌の診断および処置におけるマーカーの使用
US8133724B2 (en) Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
CN105980576B (zh) 用于源自乳腺癌的骨转移癌的预后和治疗的方法
WO2005100998A2 (en) Membrane markers for use in cancer diagnosis and therapy
US11041213B2 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
WO2013033629A2 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
US9885720B2 (en) Methods for detecting and treating cancer
EP3516071B1 (en) Methods and pharmaceutical compositions for the treatment of lung cancer
US8841422B2 (en) Human androgen receptor alternative splice variants
US10563265B2 (en) Use of RHOA in cancer diagnosis and inhibitor screening
US11029313B2 (en) Method of treating cervical neoplasia in patients infected with human papilloma virus
JP2008169132A (ja) Ｌｉｎ７ｃの癌の転移診断への応用
JP2005511552A (ja) 乳癌において増幅される推定癌遺伝子であるｉｂｃ−１（浸潤乳癌−１）

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100707

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101214